Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells - PubMed (original) (raw)
Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells
H J Chen et al. Br J Cancer. 2000 May.
Abstract
Vascular endothelial growth factor (VEGF) is one of the most potent factors for stimulating angiogenesis, an essential process required for expansion of primary tumour and dissemination of malignant cells. To investigate the possible role of VEGF in facilitating metastasis of prostate cancer via stimulating angiogenesis, we have used Northern and slot blotting, reverse transcription polymerase chain reaction, nucleotide sequence analysis and enzyme-linked immunosorbent assay to compare the VEGF expression in series of human and rat cell lines with either benign or malignant characteristics. We have also employed the chick chorioallantoic membrane (CAM) assay to measure the angiogenic activity of the VEGF derived from both benign and malignant cells. The level of VEGF mRNA expressed in the seven malignant human and rat cell lines is 3.5- to 10-fold higher than that expressed in the benign cell lines. The three metastatic variants, generated by transfection of a benign cell line with DNA extracted from prostate carcinoma cells, expressed 2.5 to 5 times more VEGF mRNA than their parental benign cells. While VEGF 121 and 165 were predominantly expressed by both the benign and malignant cells, the transcript representing VEGF 189 isoform was only detected in the malignant cells. At protein level, three human malignant cell lines produced more VEGF (2.7-7.9 ng ml(-1)) than the benign cell line (1.3 ng ml(-1)). CAM assay detected a VEGF-dependent angiogenic activity in the medium from malignant cells, but only a relatively weak VEGF-independent activity in the medium from benign cells. These results demonstrated that malignant cells did over-express VEGF and only the VEGF derived from malignant cells was angiogenically active. Thus, we suggest that the VEGF produced by malignant cells might play an important role in facilitating metastasis of prostatic cancer.
Similar articles
- Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Balbay MD, et al. Clin Cancer Res. 1999 Apr;5(4):783-9. Clin Cancer Res. 1999. PMID: 10213213 - Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate.
Ravindranath N, Wion D, Brachet P, Djakiew D. Ravindranath N, et al. J Androl. 2001 May-Jun;22(3):432-43. J Androl. 2001. PMID: 11330643 - A potential autocrine role for vascular endothelial growth factor in prostate cancer.
Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD. Jackson MW, et al. Cancer Res. 2002 Feb 1;62(3):854-9. Cancer Res. 2002. PMID: 11830543 - Implication of vascular endothelial growth factor in the development and metastasis of human cancers.
Arii S, Mori A, Uchida S, Fujimoto K, Shimada Y, Imamura M. Arii S, et al. Hum Cell. 1999 Mar;12(1):25-30. Hum Cell. 1999. PMID: 10457902 Review. - Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy.
Harmey JH, Bouchier-Hayes D. Harmey JH, et al. Bioessays. 2002 Mar;24(3):280-3. doi: 10.1002/bies.10043. Bioessays. 2002. PMID: 11891765 Review.
Cited by
- Comparison of vascular endothelial growth factor/vascular endothelial growth factor receptor 2 expression and its relationship to tumor cell proliferation in canine epithelial and mesenchymal tumors.
Kimura M, Miyahara K, Yamasaki M, Uchida N. Kimura M, et al. J Vet Med Sci. 2022 Jan 24;84(1):133-141. doi: 10.1292/jvms.21-0388. Epub 2021 Nov 25. J Vet Med Sci. 2022. PMID: 34819426 Free PMC article. - A novel cutaneous Fatty Acid-binding protein-related signaling pathway leading to malignant progression in prostate cancer cells.
Bao Z, Malki MI, Forootan SS, Adamson J, Forootan FS, Chen D, Foster CS, Rudland PS, Ke Y. Bao Z, et al. Genes Cancer. 2013 Jul;4(7-8):297-314. doi: 10.1177/1947601913499155. Genes Cancer. 2013. PMID: 24167657 Free PMC article. - Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.
Hu J, Chen C, Su Y, DU J, Qian X, Jin Y. Hu J, et al. Exp Ther Med. 2012 Dec;4(6):1045-1050. doi: 10.3892/etm.2012.702. Epub 2012 Sep 10. Exp Ther Med. 2012. PMID: 23226772 Free PMC article. - Perlecan and tumor angiogenesis.
Jiang X, Couchman JR. Jiang X, et al. J Histochem Cytochem. 2003 Nov;51(11):1393-410. doi: 10.1177/002215540305101101. J Histochem Cytochem. 2003. PMID: 14566013 Free PMC article. Review. - Calponin h1 suppresses tumor growth of Src-induced transformed 3Y1 cells in association with a decrease in angiogenesis.
Kaneko M, Takeoka M, Oguchi M, Koganehira Y, Murata H, Ehara T, Tozuka M, Saida T, Taniguchi S. Kaneko M, et al. Jpn J Cancer Res. 2002 Aug;93(8):935-43. doi: 10.1111/j.1349-7006.2002.tb01340.x. Jpn J Cancer Res. 2002. PMID: 12716472 Free PMC article.
References
- Br J Haematol. 1999 Dec;107(3):605-10 - PubMed
- Prostate. 1998 Jul 1;36(2):71-9 - PubMed
- Int J Cancer. 1978 Mar 15;21(3):274-81 - PubMed
- Invest Urol. 1979 Jul;17(1):16-23 - PubMed
- Cancer Res. 1983 Apr;43(4):1809-18 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous